Skip to main content
Menu
US
oncology-evaluation1920
Application Note

CDK signaling in oncology: evaluate phosphorylation events trigged by DNA damage

DNA double-strand breaks, like those induced by the widely used chemotherapy drug etoposide, trigger a DNA damage response that activates a variety of repair mechanisms, including the phosphorylation of the histone protein component H2AX. DNA damage can directly affect cell cycle progression by modulating levels of an important cell cycle regulator – cyclin-dependent kinase 1 (CDK1).

In this application note, you will learn how to:

  • Evaluate DNA damage induced by etoposide treatment using phosphorylated (Ser139) histone H2AX as a biomarker for the detection of DNA double-strand breaks
  • Utilize AlphaLISASureFire® Ultra™ technology to characterize changes in crucial cell cycle events by measuring both phospho- and total target proteins from the same cell lysate sample

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

CDK signaling in oncology: evaluate phosphorylation events trigged by DNA damage